Hydroxypiperone hydrochloride, a class 1.1 new drug of Huahai pharmaceutical, has obtained the clinical approval, and the industrial upgrading is in progress

Introduction to this report: the company announced that 1.1 type of chemical drug, mepyridone hydrochloride, has obtained the approval of clinical trials The company has continued to lay out in the field of bio generic drugs and new central nervous drugs, and the industrial upgrading has been continuously promoted, maintaining the overweight rating Key points of investment: Class 1 new drugs have obtained the approval of clinical trials, and the industrial upgrading is in progress, maintaining the overweight rating The company announced that 1.1 new antidepressant mepyridone hydrochloride was approved for clinical trial, which is another important progress made in the process of industrial upgrading, adding impetus to the medium and long-term development of the company In recent years, the company's export of preparations has entered the harvest period, and its short-term performance is not in doubt The EPS forecast for 2015-2017 is maintained at 0.55/0.70/0.87 yuan, the target price is maintained at 33 yuan, and the overweight rating is maintained To create the star of the future of central nervous system drugs According to the published test results, mepyridone hydrochloride has the same activity as verazolone in preclinical animal experiments, and the effective dose is lower, and it shows that its specific function is stronger than the first-line drugs fluoxetine and duloxetine Verazodone (trade name viibryd) is an antidepressant drug approved by FDA in 2011, with sales volume of US $163 / 199 million in 2012 / 2013, peak sales volume of fluoxetine original research drug of US $2.6 billion, and global sales volume of duloxetine original research drug of US $5.2 billion in 2013 The compound has been patented in many countries, which does not exclude the possibility of clinical research and application abroad in the future We expect that if the drug can be successfully launched, it will become a heavyweight product in the field of antidepressant According to the previously announced cooperation framework with the Academy of Military Sciences, the company is expected to invest in more central nervous system drug development projects Industrial upgrading is advancing step by step The company has made a lot of important progress in the field of preparation export and bio generic drugs The export of overseas preparations has entered the harvest period In addition, the clinical trials of bio generic drugs such as adamumumab and bevacizumab have been carried out in Europe and the United States, and the industrial upgrading and transformation are advancing step by step Although the research project does not contribute to the performance in short term, it has greatly enriched the company's product echelon, with the help of its increasingly mature marketing channels of preparations, to add momentum to the medium and long-term development.